If you are researching hydrogel injections for joint pain, you may be wondering whether they have FDA approval. The answer depends on the specific product and condition being treated. Understanding this distinction is important, particularly because regulatory requirements differ between the United States and the United Kingdom.

Are Hydrogel Injections FDA Approved?

There is no single FDA status that applies to all hydrogel injections. The term describes a broad category of injectable products made from different materials and designed for different purposes.

The US Food and Drug Administration assesses medical devices according to the individual product and its intended use. This means one injectable hydrogel may have FDA approval for knee osteoarthritis, while another product using different technology may not.

For example, the FDA approved HYMOVIS® ONE, a hyaluronic acid intra-articular device, in April 2025 for treating pain caused by knee osteoarthritis in certain patients who have not responded adequately to conservative treatment or simple analgesics.

However, this approval applies specifically to HYMOVIS ONE. It does not mean every injectable hydrogel has FDA authorisation or that one approved product can automatically be used for another condition.

What About Arthrosamid?

If by hydrogel injections you mean Arthrosamid®, the regulatory position is different.

Arthrosamid is a non-biodegradable polyacrylamide hydrogel designed for the symptomatic treatment of adults with knee osteoarthritis. It is injected directly into the knee joint and differs from hyaluronic acid-based injections in its composition and how it behaves within the joint.

As of September 2026, Arthrosamid has not received FDA clearance or approval for treating human knee osteoarthritis in the United States. Contura Orthopaedics stated in an April 2026 publication that the company was in discussions with the FDA regarding its use as a medical device in the US. The same publication confirms that Arthrosamid received CE marking in 2021 for adult patients with symptoms of knee osteoarthritis.

This distinction is important. A treatment being available or appropriately regulated in one country does not automatically mean it has received authorisation from another country's regulator.

Does FDA Approval Matter for Patients in the UK?

For patients receiving treatment in the UK, FDA approval is not the regulatory standard that determines whether a medical device can be placed on the British market.

In Great Britain, medical devices are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The UK currently recognises qualifying CE-marked medical devices under transitional arrangements, with applicable timelines extending to 2028 or 2030 depending on the device and regulatory route.

Therefore, when considering hydrogel injections in the UK, it is more useful to ask whether the specific product meets the appropriate UK regulatory requirements and whether it is intended for your particular condition.

Arthrosamid's stated indication is symptomatic knee osteoarthritis in adults. This does not mean it will be appropriate for every person with knee pain, nor does it mean it should be used for other joints or conditions simply because it is a hydrogel.

A specialist should first establish the cause and severity of your symptoms. They can then review your medical history, previous treatments and overall health before deciding whether an injectable treatment is suitable.

What Should You Check Before Treatment?

Before choosing any injectable treatment, make sure you know exactly which product your clinician is recommending. Similar-sounding hydrogel injections can have different ingredients, regulatory approvals and intended uses.

It can be helpful to ask:

• What is the exact name of the injection?

• Is it indicated for my diagnosed condition?

• What regulatory status does it have in the UK?

• What evidence supports its use for people like me?

• What are the potential risks and alternatives?

• Why is this treatment being recommended for my particular joint?

These questions can help you separate general claims about hydrogel technology from information that applies specifically to your treatment.

Understand Whether Hydrogel Treatment Is Right for You

FDA approval depends on the exact product and indication, so it is important not to treat all hydrogel injections as interchangeable. Arthrosamid is CE marked for symptomatic knee osteoarthritis in adults but, as of September 2026, has not received FDA authorisation for that indication in the United States.

For UK patients, the more relevant questions concern UK regulatory status, clinical suitability and whether the treatment is appropriate for your individual condition.

At Regenesis, we help patients understand their options for managing joint pain and osteoarthritis, including non-surgical orthopaedic treatments where appropriate. Explore our information on knee osteoarthritis and injectable treatments, or contact our team to discuss which options may be suitable for you.